Yes. There are several cost-effectiveness analyses (CEAs) and budget-impact studies published since Wegovy (semaglutide 2.4 mg weekly) was approved for obesity and weight management. The overall message from these studies is nuanced and often depends on the country, perspective (payer, societal), time horizon, and especially drug price and how long weight loss is maintained.
Key takeaways by region (in broad terms):
- United States: Most CEAs that model Wegovy for obesity find it not cost-effective at the current U.S. price from a typical payer perspective, with incremental cost-effectiveness ratios (ICERs) commonly above conventional willingness-to-pay thresholds (often cited as around $100,000 per QALY, though thresholds vary). Results improve only under scenarios with substantial long-term weight loss maintenance, strong reductions in obesity-related health risks, or when the drug price is lower (discounts or rebates). The exact ICERs vary widely by model assumptions.
- United Kingdom: NICE and other UK-based analyses generally conclude Wegovy is not cost-effective for obesity at current UK prices, though the conclusion can change with substantial price reductions or for specific high-risk subgroups.
- Canada and other markets: CEAs in Canada and several other countries tend to show more favorable or less favorable results depending on local drug prices, health-state utilities, and time horizons. In many cases, cost-effectiveness improves with longer time horizons, better adherence, and greater reductions in obesity-related comorbidities.
What drives the results
- Drug price and payer discounting: The most influential factor. Lower list prices or payer-sponsored discounts improve cost-effectiveness.
- Time horizon and maintenance: If weight loss is maintained long-term, cost-effectiveness tends to improve; if weight is regained quickly after stopping, the ICER worsens.
- Population and comorbidity context: People with higher baseline risk (e.g., obesity plus diabetes or cardiovascular risk) may see more favorable cost-effectiveness due to greater potential health benefits.
- Comparator and alternatives: Results depend on whether Wegovy is compared to lifestyle intervention alone, other anti-obesity drugs, or standard care.
Would you like me to pull recent, country-specific studies and summarize their methods, assumptions, and exact ICER values (with citations)? If you tell me a country or region (e.g., US payer perspective, UK NICE, Canada, Australia), I can compile a concise list of representative studies and their key findings.